Publications by authors named "Wouter Mellema"

Claim this Profile
C
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.
Wouter W Mellema, Lucie Masen-Poos, Egbert F Smit, Lizza E L Hendriks, Joachim G Aerts

Lung Cancer· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
Floris H Groenendijk, Wouter W Mellema, Eline van der Burg, Eva Schut, Michael Hauptmann

Int J Cancer· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report.
Wouter W Mellema, Sjaak A Burgers, Egbert F Smit

Lung Cancer· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Difference in outcome between types of KRAS mutation may point toward difference in tumor biology.
Wouter W Mellema, Anne-Marie C Dingemans, Marianne Jonker, Egbert F Smit

J Thorac Oncol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer.
Johannes C van der Mijn, Nik Sol, Wouter Mellema, Connie R Jimenez, Sander R Piersma

J Extracell Vesicles· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy.
Wouter W Mellema, Dorien van der Hoek, Pieter E Postmus, Egbert F Smit

Lung Cancer· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Wouter W Mellema, Anne-Marie C Dingemans, Erik Thunnissen, Peter J F Snijders, Jules Derks

J Thorac Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Anne-Marie C Dingemans, Wouter W Mellema, Harry J M Groen, Atie van Wijk, Sjaak A Burgers

Clin Cancer Res· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low molecular weight heparins in the treatment of lung cancer.
Wouter W Mellema, Egbert F Smit, Anne-Marie C Dingemans

Expert Opin Investig Drugs· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis